ArticleFrontiers in immunology2025
Evaluation of the viability and functionality of human peripheral blood mononuclear cells cryopreserved up to 2 years in animal-protein-free freezing media compared to the FBS-supplemented reference medium.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cryopreservation of peripheral blood mononuclear cells (PBMCs) is crucial for consistent analysis in immunological studies and clinical trials. Traditional freezing media often contain fetal bovine serum (FBS), which raises ethical concerns and the risk of pathogen transmission, and dimethyl sulfoxide (DMSO), known for its cytotoxic effects. This study evaluates the viability, yield, phenotype, and functionality of PBMCs cryopreserved in several commercially available animal-protein-free media, some with reduced or no DMSO, compared with a reference medium over 2-years. Methods: PBMCs from 11 healthy volunteers were cryopreserved in a reference medium (FBS + 10% DMSO) and nine alternative serum-free media with varying DMSO concentrations. Cell viability and functionality were assessed at 3 weeks (M0), 3 months (M3), 6 months (M6), 1 year (M12), and 2 years (M24) post-freezing. Media with DMSO concentrations below 7.5% were excluded after M0 due to lower viability. Cell functionality was assessed using various assays including cytokine secretion profiles, T and B FluoroSpot, and intracellular cytokine staining. Results: PBMCs cryopreserved in CryoStor CS10 and NutriFreez D10 maintained high viability and functionality, comparable to the FBS10 reference medium, across all time points. Bambanker D10 displayed a comparable viability but tended to diverge from the FBS10 reference medium in terms of T cell functionality. CryoStor CS7.5, while showing promising results, was eliminated due to being a mixture of CS10 and CS5, which could potentially introduce errors in preparation. Media with < 7.5% DMSO showed significant viability loss and were eliminated after the initial assessments. Serum-free media with 10% DMSO, comparable to FBS-based media, effectively preserved PBMC immune response. Conclusions: CS10 and NutriFreez D10, both serum-free media containing 10% DMSO, are viable alternatives to FBS-based media for the long-term cryopreservation of PBMCs. These media ensure comparable cell viability and functionality, supporting their application in clinical and research settings to address the important drawbacks associated with FBS use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.